Arcus Biosciences, Inc.
RCUSNYSEHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $33.0M | $51.0M | $37.0M | $38.0M | $383.0M | $77.5M |
| Operating income | −$386.0M | −$330.0M | −$340.0M | −$280.0M | $54.0M | −$124.2M |
| Net income | −$353.0M | −$283.0M | −$307.0M | −$267.0M | $53.0M | −$27.8M |
| Total assets | $1.14B | $1.15B | $1.09B | $1.34B | $1.59B | $772.3M |
| Total liabilities | — | — | — | — | $750.4M | $270.0M |
| Equity | $631.0M | $485.0M | $462.0M | $657.0M | $842.0M | $502.0M |
| EPS (diluted) | $-3.29 | $-3.14 | $-4.15 | $-3.71 | $0.71 | $-2.24 |
| Shares out. | 105.8M | 90.9M | 73.0M | 71.1M | 70.9M | 46.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1169.7%
- Net margin
- −1069.7%
- Return on equity
- −55.9%
- Return on assets
- −31.0%
- Return on capital (ROCE)
- −42.5%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $5.96
- Revenue growth (YoY)
- −35.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- 11.3%high accruals
- Piotroski F-Score
- 0/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 5 warning● 0 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- High accruals — earnings-quality risk
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2026-03Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
- Phase 3Active Not Recruitingreadout ~2026-06A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
- Phase 1Active Not Recruitingreadout ~2026-11A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
- Phase 2Active Not Recruitingreadout ~2027-01A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
- Phase 1Active Not Recruitingreadout ~2027-05A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
- Phase 2Active Not Recruitingreadout ~2027-05Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
- Phase 3Recruitingreadout ~2028-04Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Phase 1Recruitingreadout ~2029-03A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Group IncPassive (13G)Mar 26, 2026
- Blackrock, Inc.Passive (13G)Jan 8, 2026
- Point72 Asset Management, L.P.Passive (13G)Nov 14, 2025
- Gilead Sciences, Inc.Activist (13D)Nov 5, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Azoy AlexanderOfficer — Chief Accounting Officer | Jun 1, 2026 | Sell | 2,562 | $25.77 |
| Ribas AntoniDirector | Dec 16, 2025 | Gift | 5,050 | $0.00 |
| Goeltz Ii Robert C.Officer — Chief Financial Officer | May 11, 2026 | Sell | 7,763 | $25.63 |
| Markus RichardOfficer — Chief Medical Officer | Jan 23, 2026 | Grant | 24,000 | $0.00 |
| Rosen Terry JOfficer — Chief Executive Officer | Jan 23, 2026 | Grant | 79,000 | $0.00 |
| Jaen Juan C.Officer — President | Jan 23, 2026 | Grant | 31,000 | $0.00 |
| Tang Carolyn C.Officer — General Counsel | Jan 23, 2026 | Grant | 24,000 | $0.00 |
| Goeltz Ii Robert C.Officer — Chief Financial Officer | Jan 23, 2026 | Grant | 24,000 | $0.00 |
| Azoy AlexanderOfficer — Chief Accounting Officer | Jan 23, 2026 | Grant | 21,050 | $0.00 |
| Jarrett JenniferOfficer — Chief Operating Officer | Jan 23, 2026 | Grant | 31,000 | $0.00 |
| Rosen Terry JOfficer — Chief Executive Officer | Jan 8, 2026 | Gift | 35,000 | $0.00 |
| Jaen Juan C.Officer — President | Jan 5, 2026 | Sell | 29,670 | $21.34 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 10.9M | 11.2 | +0.1% |
| Apr 30, 2026 | 10.9M | 6.5 | -1.8% |
| Apr 15, 2026 | 11.1M | 12.2 | +12.1% |
| Mar 31, 2026 | 9.9M | 8.1 | +14.7% |
| Mar 13, 2026 | 8.6M | 6.1 | -7.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 5, 2026
- Other material eventApr 20, 2026
- Director / officer changeMar 23, 2026
- Results of operationsFeb 25, 2026
- Entered a material agreement · New financial obligationDec 18, 2025
- Other material eventDec 12, 2025
- Other material eventNov 3, 2025
- Results of operationsOct 28, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.